Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学NSCLC, ALK Lorlatinib

Benjamin Solomon

MBBS, PhD

🏢Peter MacCallum Cancer Centre🌐Australia

Medical Oncologist; Head, Cancer Medicine

48
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Benjamin Solomon led the CROWN trial that established lorlatinib as a first-line standard of care for ALK-positive NSCLC with superior CNS efficacy and prolonged PFS compared to crizotinib. His research focuses on CNS penetration of ALK inhibitors and management of brain metastases in ALK-rearranged disease. He has made major contributions to understanding lorlatinib's activity against diverse compound ALK resistance mutations. He is a key voice in global thoracic oncology guideline development.

Share:

🧪Research Fields 研究领域

lorlatinib first-line
CROWN trial
ALK CNS penetration
ALK compound mutations
third-generation ALK inhibitors

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Benjamin Solomon 的研究动态

Follow Benjamin Solomon's research updates

留下邮箱,当我们发布与 Benjamin Solomon(Peter MacCallum Cancer Centre)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment